Lazertinib: a novel EGFR-TKI therapy for non-small cell lung cancer

Area of Science:

• Oncology
• Pharmacology

Background:

• Non-small cell lung cancer (NSCLC) is the most common lung cancer type.
• Advanced NSCLC and resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) present significant treatment challenges.
• Lazertinib is a third-generation EGFR TKI targeting EGFR mutations, including T790M.

Purpose of the Study:

• To review lazertinib's development, mechanism of action, clinical efficacy, and safety.
• To evaluate lazertinib's potential in treating advanced NSCLC, particularly in cases of resistance and brain metastases.

Main Methods:

• Review of preclinical studies comparing lazertinib to osimertinib.
• Analysis of clinical trial data on lazertinib monotherapy and combination therapy with amivantamab.
• Examination of emerging resistance mutations and future therapeutic strategies.

Main Results:

• Preclinical data indicate lazertinib's superior selectivity for mutant EGFR and enhanced blood-brain barrier penetration compared to osimertinib.
• Clinical trials demonstrate improved progression-free survival and response duration for lazertinib in advanced NSCLC.
• Lazertinib shows efficacy as both a monotherapy and in combination with amivantamab.

Conclusions:

• Lazertinib is a promising treatment for EGFR-mutated NSCLC, particularly for patients with brain metastases or resistance to prior EGFR TKIs.
• Emerging resistance mutations like C797S necessitate ongoing research into novel therapies, including combination treatments and fourth-generation TKIs.
• Continued innovation is crucial for optimizing treatment outcomes in NSCLC.